ImmunoGen - Comparative Multiple Analysis

ImmunoGen (Comparative Multiple Analysis)


Notes on the Comparative Multiple Analysis of ImmunoGen

WikiWealth compares ImmunoGen's revenue, EBITDA, and EBIT multiples to their peers in order to determine the appropriate fair valuation. Click in the top right corner to experiment with ImmunoGen's comparative analysis.

Notes from the analysis:

1. WikiWealth uses quantitative measures to determine the multiple range for ImmunoGen.
2. Free cash flow to the firm (FCF) multiple is free cash flow to equity holders plus interest owed to ImmunoGen's debt holders.
3. Multiples incorporate benefits due to economies of scale; WikiWealth compares absolute enterprise value multiples to competitor's multiples.
4. WikiWealth excludes outliers when calculating individual company multiples.

Helpful Information for ImmunoGen's Analysis

How does this work? The Comparative Investment Analysis determines the value of ImmunoGen by comparing ImmunoGen financial ratios, prices, growth rates, margins, etc. to those of relevant peer groups.

Value Investing Importance? This method is widely used by investment professionals to determine the correct price of investments, especially initial public offerings (IPOs). It is one element of WikiWealth's three Wall Street approaches used to determine the correct fair value of ImmunoGen.

See the ImmunoGen cash flow (DCF) analysis for a completely different approach that's popular on Wall Street for determining the value of an investment in ImmunoGen.

Also, see the ImmunoGen's buffett intrinsic valuation analysis for WikiWealth's attempt to replicate the investing formula's used by Warren Buffett and ImmunoGen's valuation conclusion for a quick summary.